30 closest matches · ranked by relevance
Chronic Diarrhea of Unknown Origin
Primary: Number of Participants With a 50 Percent Decrease in Mean Stool Count — 17 Participants
Irritable Bowel Syndrome
Primary: Number of Participants With Post Infectious Irritable Bowel Syndrome — 23; 114 participants
Irritable Bowel Syndrome
Primary: Change in Mean Daily Abdominal Pain — 5.2; 5.3; 3.9; 3.8 score on a scale — p=0.78
Chronic Functional Diarrhea of Unknown Origin
Primary: Mean Change From Baseline in Blood Lead Levels During the Treatment Period and Post-treatment Follow-up Period — 0.120; 0.306; 0.095; 0.359 nanograms per millilitre…
Gastrointestinal Inflammation Associated With CVID · CVID Enteropathy
Primary: Number of Participants With Increase in Infection or Serious Adverse Events (SAEs) Related to Single Dose Administration of Ustekinumab — 0 participants
Diarrhea
Primary: Percent of Patients With Return Toward a Normal Fecal Bile Acid Pattern — 100 percentage of participants
Irritable Bowel Syndrome · Small Intestinal Bacterial Overgrowth
Primary: Global Improvement Scale — 4.3; 4.3 units on a scale — p=0.26
Cholera
Primary: Stool Output Volume During Treatment Period. — 9.82; 9.31; 5.69; 7.29 ml/kg·h-1 — p=0.003
Diarrhea · Gastroenteritis
Primary: Duration of Diarrhea in Acute Diarrheal Illnesses in a Developed Nation While Taking Zinc or Placebo. — 73; 72; 48; 76.8 Hours — p=0.88
Breast Cancer
Primary: Diarrhea for >= 2 Consecutive Days — 68; 69.6; 65.2; 72.2 percentage of patients
Irritable Bowel Syndrome · Colitis, Ulcerative · Crohn Disease
Primary: Colonic-Mucosa Associated Microbial Species Per Compiled Participants in 5 Different Arms — 40; 30; 23; 23 microbial species population
Celiac Disease
Primary: Baseline Gastrointestinal Symptom Rating Scale (GSRS) Score — 2.7; 2.8 Score on a scale
Cholera
Primary: Diarrheal Stool Output Rate — 25.42; 32.57 mL/hour — p=0.2254
Sphincter of Oddi Dysfunction
Primary: The Primary Outcome Measure Was a Patient Global Assessment of Change (PGIC) Scale. — 3.3 units on a scale
Diarrhea · Cholera
Primary: Stool Output — 4769; 4742; 1688; 1704 gram — p=0.9941
Irritable Bowel Syndrome With Diarrhea
Primary: Change From Baseline in Average Bristol Stool Form Scale (BSFS) Score Over 4 Weeks of Treatment Period — 5.89; 5.34; -1.25; -1.09 score on a scale
Crohn Disease
Primary: Change in FCP in Group 2 Participants — 1501 mcg/g — p=1.0
Inflammatory Bowel Disease · Perianal Fistula · Perianal Abscess
Primary: Prevalence of Inflammation as Diagnosed by Capsule Endoscopy — 6 participants
Diarrhoea
Primary: Time (in Hours) Between the 1st Intake of IQP-MM-101 and First Formed or Hard Stool (Type 6 to 1) Followed by a Non Watery Stool (Type 6 to 1) — 21.30 hours
Intestinal Diseases · Irritable Bowel Syndrome · Constipation
Primary: Lactulose:C13 Mannitol Excretion Ratio 8-24hrs. — 0.01; 0.02 Ratio — p=0.87
Chronic Diarrhea · Irritable Bowel Syndrome With Diarrhea · Bile Acid Malabsorption
Primary: Fasting Serum C4 Levels — 2.2; 50.4 ng/ML
Crohn's Disease
Primary: Change in Disease Activity by Harvey Bradshaw Index — -5; -3 score on a scale
Crohn Disease
Primary: Sustained Relapse-free Remission — 6; 5 Participants
Acute Diarrhoea
Primary: Time to Recovery — 66.0; 68.6 Hours — p==0.2524
Recurrent C. Difficile Associated Diarrhea
Primary: Safety of Fresh, Frozen or Lyophilized Intestinal Bacteria From Healthy Donors Given by Colonoscopy for Therapy in Subjects With Recurrent C. Difficile Associated…
Irritable Bowel Syndrome
Primary: Within and Between Group Comparisons of Disease Severity as Determined by Irritable Bowel Syndrome-Symptom Severity Score (IBS-SSS) — 282; 309; 221; 236 units on a scale
Clostridium Difficile Infection
Primary: The Number of Cases of CDI — 103; 0 Participants
Clostridium Difficile Infection
Primary: Patient Demographics — 54; 46; 63; 29 participants
Inflammatory Bowel Diseases (IBD) · Crohn's Disease (CD) · Ulcerative Colitis (UC)
Primary: Number of Occurrences of Adverse Events at 6 Months According to Adverse Event Term — 11; 5; 5; 3 Events
Chronic Abdominal Pain · Small Intestinal Bacterial Overgrowth
Primary: The Number of Participants at Baseline With SIBO — 14; 44; 24 Participants